{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:43:42Z","timestamp":1788000222993,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002001","name":"NIHR Evaluation Trials and Studies Coordinating Centre","doi-asserted-by":"publisher","award":["NIHR128210"],"award-info":[{"award-number":["NIHR128210"]}],"id":[{"id":"10.13039\/501100002001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","plefa.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.plefa.2023.102570","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T18:32:50Z","timestamp":1679596370000},"page":"102570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial"],"prefix":"10.1016","volume":"192","author":[{"given":"H.","family":"Fuller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Race","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Downing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Loadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.plefa.2023.102570_bib0001","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-med-060319-120913","article-title":"Aspirin in the prevention of colorectal neoplasia","volume":"72","author":"Drew","year":"2021","journal-title":"Ann. Rev. Med."},{"key":"10.1016\/j.plefa.2023.102570_bib0002","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10555-018-9744-y","article-title":"Omega-3 polyunsaturated fatty acids as adjuvant therapy of colorectal cancer","volume":"37","author":"Volpato","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.plefa.2023.102570_bib0003","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ceb.2005.02.005","article-title":"Cyclooxygenases, peroxide tone and the allure of fish oil","volume":"17","author":"Smith","year":"2005","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.plefa.2023.102570_bib0004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.prostaglandins.2015.07.004","article-title":"Aspirin and lipid mediators in the cardiovascular system","volume":"121","author":"Schr\u00f6r","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.plefa.2023.102570_bib0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bbalip.2011.06.007","article-title":"Chiral lipidomics of E-series resolvins: aspirin and the biosynthesis of novel mediators","volume":"1811","author":"Oh","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.plefa.2023.102570_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00852","article-title":"Omega-3 polyunsaturated fatty acids and their bioactive metabolites in gastrointestinal malignancies related to unresolved inflammation. A review","volume":"10","author":"Irun","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.plefa.2023.102570_bib0007","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/mc.22629","article-title":"Plasma lipoxin A4 and resolvin D1 are not associated with reduced adenoma risk in a randomized trial of aspirin to prevent colon adenomas","volume":"56","author":"Fedirko","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.plefa.2023.102570_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101605","article-title":"Specialized pro-resolving mediators as modulators of immune responses","author":"Julliard","year":"2022","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.plefa.2023.102570_bib0009","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10555-011-9311-2","article-title":"Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer","volume":"30","author":"Janakiram","year":"2011","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.plefa.2023.102570_bib0010","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.ajpath.2022.07.004","article-title":"Resolvin E1 reduces tumor growth in a xenograft model of lung cancer","volume":"192","author":"Kantarci","year":"2022","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.plefa.2023.102570_bib0011","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.4049\/jimmunol.178.6.3912","article-title":"Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation","volume":"178","author":"Arita","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.plefa.2023.102570_bib0012","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/carcin\/bgy117","article-title":"An omega-3 polyunsaturated fatty acid derivative, 18-HEPE, protects against CXCR4-associated melanoma metastasis","volume":"39","author":"Li","year":"2018","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.plefa.2023.102570_bib0013","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1016\/S0140-6736(18)31775-6","article-title":"Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2x2 factorial trial","volume":"392","author":"Hull","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.plefa.2023.102570_bib0014","doi-asserted-by":"crossref","DOI":"10.3310\/eme06040","article-title":"Eicosapentaenoic acid and\/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT","volume":"6","author":"Hull","year":"2019","journal-title":"Efficacy Mech. Eval."},{"key":"10.1016\/j.plefa.2023.102570_bib0015","doi-asserted-by":"crossref","unstructured":"A. Downing, H. Fenton, C. Nickerson, et\u00a0al., Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: evidence of \u2018rebound\u2019 elevated colorectal polyp risk after short-term aspirin use, Submitted. (2023).","DOI":"10.1111\/apt.17646"},{"key":"10.1016\/j.plefa.2023.102570_bib0016","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.biochi.2020.08.015","article-title":"Eicosapentaenoic acid and docosahexaenoic acid derived specialised pro-resolving mediators: concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake","volume":"178","author":"Calder","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.plefa.2023.102570_bib0017","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-14-237","volume":"14","author":"Hull","year":"2013","journal-title":"Trials"},{"key":"10.1016\/j.plefa.2023.102570_bib0018","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.arr.2018.09.004","article-title":"Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: focus on atherothrombosis","volume":"48","author":"Simeone","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.plefa.2023.102570_bib0019","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1055\/s-2007-1005785","article-title":"Endotoxemia and mediator release during colonoscopy","volume":"27","author":"Berger","year":"1995","journal-title":"Endoscopy"},{"key":"10.1016\/j.plefa.2023.102570_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.34459","article-title":"Combination of naproxen and a novel chemically-stable eicosapentaenoic acid analogue provide synergistic tumor protection in Pirc rats","author":"Beach","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.plefa.2023.102570_bib0021","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ajcn\/nqz016","article-title":"Plasma oxylipins respond in a linear dose-response manner with increased intake of EPA and DHA: results from a randomized controlled trial in healthy humans","volume":"109","author":"Ostermann","year":"2019","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.plefa.2023.102570_bib0022","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaip.2016.11.021","article-title":"Plasma 15-Hydroxyeicosatetraenoic acid predicts treatment outcomes in aspirin-exacerbated respiratory disease","volume":"5","author":"Jerschow","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.plefa.2023.102570_bib0023","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.atherosclerosis.2020.11.018","article-title":"EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: a randomized, double-blind, crossover study","volume":"316","author":"So","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plefa.2023.102570_bib0024","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.clnu.2012.12.010","article-title":"Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors","volume":"32","author":"Dawczynski","year":"2013","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.plefa.2023.102570_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.plefa.2018.04.004","article-title":"The effects of alcohol on plasma lipid mediators of inflammation resolution in patients with type 2 diabetes mellitus","volume":"133","author":"Barden","year":"2018","journal-title":"Prostaglandins Leukotrienes Essent. Fatty Acids"},{"key":"10.1016\/j.plefa.2023.102570_bib0026","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3945\/ajcn.115.116384","article-title":"Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin","volume":"102","author":"Barden","year":"2015","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.plefa.2023.102570_bib0027","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1194\/jlr.M045583","article-title":"Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation","volume":"55","author":"Barden","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.plefa.2023.102570_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11030137","article-title":"Collection and storage of human plasma for measurement of oxylipins","volume":"11","author":"Polinski","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.plefa.2023.102570_bib0029","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3324\/haematol.2019.219519","article-title":"Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction","volume":"105","author":"Kooij","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.plefa.2023.102570_bib0030","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1096\/fj.201600360R","article-title":"Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid eicosapentaenoic acid","volume":"30","author":"Markworth","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.plefa.2023.102570_bib0031","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.7150\/jca.32456","article-title":"Colorectal cancer is associated with a deficiency of lipoxin A4, an endogenous anti-inflammatory mediator","volume":"10","author":"Liu","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.plefa.2023.102570_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.plefa.2020.102219","article-title":"Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation","volume":"164","author":"Lamon-Fava","year":"2021","journal-title":"Prostaglandins Leukotrienes Essent. Fatty Acids"},{"key":"10.1016\/j.plefa.2023.102570_bib0033","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36679-4","article-title":"Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation","volume":"8","author":"Norris","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.plefa.2023.102570_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196398","article-title":"Celecoxib use and circulating oxylipins in a colon polyp prevention trial","volume":"13","author":"Martinez","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.plefa.2023.102570_bib0035","article-title":"One-year effects of omega-3 treatment on fatty acids, oxylipins, and related bioactive lipids and their associations with clinical lipid and inflammatory markers: findings from a substudy of the vitamin D and omega-3 trial (VITAL)","volume":"10","author":"Demer","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.plefa.2023.102570_bib0036","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/mnfr.200500063","article-title":"The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis","volume":"49","author":"Staprans","year":"2005","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.plefa.2023.102570_bib0037","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.20042031","article-title":"Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator Resolvin E1","volume":"201","author":"Arita","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.plefa.2023.102570_bib0038","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1734-1140(10)70311-X","article-title":"Cytochrome P450-dependent metabolism of \u03c9-6 and \u03c9-3 long-chain polyunsaturated fatty acids","volume":"62","author":"Arnold","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.plefa.2023.102570_bib0039","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1194\/jlr.M047514","article-title":"Hydroxyeicosapentaenoic acids from the Pacific krill show high ligand activities for PPARs","volume":"55","author":"Yamada","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.plefa.2023.102570_bib0040","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.gtc.2010.08.014","article-title":"Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer","volume":"39","author":"Wang","year":"2010","journal-title":"Gastroenterol. Clin. North Am."}],"container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095232782300039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095232782300039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:13:10Z","timestamp":1760602390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095232782300039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"alternative-id":["S095232782300039X"],"URL":"https:\/\/doi.org\/10.1016\/j.plefa.2023.102570","relation":{},"ISSN":["0952-3278"],"issn-type":[{"value":"0952-3278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins, Leukotrienes and Essential Fatty Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plefa.2023.102570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102570"}}